SAN FRANCISCO, April 1, 2008 /PRNewswire/ -- DiObex, Inc., a privately
held biotechnology company focused on the development of therapeutics to
treat metabolic diseases, announced today that a scientific poster relating
to DIO-902 (levdexketoconazole) is being presented at the American Society
for Clinical Pharmacology and Therapeutics annual meeting on Saturday,
April 5th in Orlando. DIO-902 is being studied in Phase 2b clinical trials
for the treatment of type 2 diabetes.

The poster, entitled "Differential Effects of Co-Administration of
Racemic Ketoconazole and Levdexketoconazole on the Pharmacokinetic Profile
of Atorvastatin," highlights the results of a study evaluating the effects
of equal doses of the single enantiomer DIO-902 and racemic ketoconazole,
on the pharmacokinetics of a single 80 mg dose of atorvastatin in healthy
volunteers. Overall, repeated oral administration of DIO-902 tablets with
atorvastatin was safe and well tolerated; in addition, DIO-902
significantly reduced cortisol levels compared with ketoconazole.

"The increase in total exposure of atorvastatin was significantly less
when it was administered with DIO-902 than with racemic ketoconazole," said
Dr. Tim Stewart, Vice President of Research at DiObex. "In addition, the
administration of DIO-902 with atorvastatin resulted in significantly
reduced cortisol levels from placebo, compared with atorvastatin
administered with racemic ketoconazole. This finding supports preclinical
evidence that DIO-902 is a more potent inhibitor of cortisol synthesis than
ketoconazole."

DIO-902 is an oral, single enantiomer of ketoconazole, a common
anti-fungal drug. DiObex is developing DIO-902 as a novel cortisol
inhibitor for treating type 2 diabetes and diabetic nephropathy. There is
growing evidence linking abnormal cortisol metabolism to both type 2
diabetes and metabolic syndrome, prompting a search for therapeutic agents
that lower levels of cortisol or block the effects of cortisol excess.
Preclinical and clinical data indicate that DIO-902 is a potent cortisol
inhibitor. Clinical data also show early trends toward reductions in HbA1c,
total cholesterol, LDL cholesterol, and C-reactive protein. Preclinical and
clinical data also suggest that DIO-902 may be a safer and more effective
agent than racemic ketoconazole.

About DiObex

DiObex, Inc. is a privately held biotechnology company developing novel
products for diabetes and metabolic diseases. DiObex has two product
candidates in four mid-stage clinical development programs. DIO-901 (very
low dose glucagon) is in development for the prevention of insulin-induced
hypoglycemia in type 1 diabetes mellitus in an extended release
subcutaneous formulation and in a convenient disposable subcutaneous
delivery device. DIO-901 has received Fast Track status from the FDA.
DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole
that is a novel cortisol synthesis inhibitor in development for type 2
diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol
activity may play an important role in the development of metabolic
syndrome, a constellation of conditions that place people at high risk for
type 2 diabetes mellitus and cardiovascular disease. For more information,
visit http://www.diobex.com.

(Date:12/8/2016)... report analyzes the worldwide markets for Biostimulants in US$ by ... Extract Based, and Others. The report also analyzes the Global ... Crops, and Others. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ...

(Date:12/8/2016)... Dec. 8, 2016 Biotheranostics today announced that ... of the Breast Cancer Index (BCI) in identifying ... are most at-risk for disease recurrence and might ... from three studies advancing the understanding of the ... tumor biology and inform decisions related to patient ...

(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...

(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...